Bipartisan senators unveil a $35 insulin cap for many privately insured people and a 10-state pilot for the uninsured.
Transitioning from a disposable, prefilled autoinjector to a reusable pen meant designing for an even better experience.
The Print on MSN
Beyond Ozempic: A look at India’s anti-obesity drug market, what’s available now & what is to come
Patent expiry unleashes low-cost generics from Indian pharmaceutical firms. A look at the options available, how they work, ...
Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
As cheaper versions enter the market and competition increases, the government is stepping in to regulate how these drugs are ...
Investor focus shifts to precision engineering firms riding AI and GLP-1 megatrends, with high growth potential but elevated ...
Sol-Millennium Medical Inc., a global medical device company focused on patient safety, clinical efficiency, and healthcare outcomes, today announced the launch of its dedicated U.S. B2B e commerce ...
SOBBING, I stared at myself in the mirror as I tried on yet another ill-fitting dress. I had Sunday brunch planned with ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk A/S’ NVO Awiqli (insulin icodec-abae), marking ...
India warns of GLP-1 drug risks as Ozempic and Wegovy prices fall, urging prescription-only use and tightening checks on ...
India drug regulator cracks down on misuse of GLP 1 weight loss drugs, expanding inspections and warnings as demand surges ...
Novo Nordisk today announced a new multi-month subscription program for Wegovy (R) (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results